Search Results
Apr 07, 2026, 09:00 ET Maven Clinic and Wellthy Partner to Deliver a Unified Family Care Platform for Employers
scale. Through its consumer platform, Maven provides direct access to virtual care across 30+ specialties, as well as dedicated hormone and GLP-1 care programs purpose-built for women.Founded in 2014 by CEO Kate Ryder, Maven Clinic has raised more than $425 million from leading healthcare
More news about: Maven Clinic
Apr 07, 2026, 08:14 ET BoomerangFX's AUVIA™ AI Clinic Co-Pilot Surpasses 1,000 Monthly Autonomous Consultations Amid Rapid Acceleration Across North America, Europe and Asia-Pacific
and operates with clinical context across a broad range of treatment categories, including aesthetic medicine, medical weight loss including GLP-1 therapies, hormone optimization, longevity services, hair restoration, and men's and women's sexual health.Dr. Stephen Mulholland, Co-Founder
More news about: BoomerangFX
Apr 07, 2026, 08:14 ET BoomerangFX's AUVIA™ AI Clinic Co-Pilot Surpasses 1,000 Monthly Autonomous Consultations Amid Rapid Acceleration Across North America, Europe and Asia-Pacific
and operates with clinical context across a broad range of treatment categories, including aesthetic medicine, medical weight loss including GLP-1 therapies, hormone optimization, longevity services, hair restoration, and men's and women's sexual health.Dr. Stephen Mulholland, Co-Founder
More news about: BoomerangFX
Apr 07, 2026, 08:14 ET BoomerangFX's AUVIA™ AI Clinic Co-Pilot Surpasses 1,000 Monthly Autonomous Consultations Amid Rapid Acceleration Across North America, Europe and Asia-Pacific
healthcare and operates with clinical context across a broad range of treatment categories, including aesthetic medicine, medical weight loss including GLP-1 therapies, hormone optimization, longevity services, hair restoration, and men's and women's sexual health.Dr. Stephen Mulholland, Co-Founder
More news about: BoomerangFX
Apr 07, 2026, 08:14 ET Der AUVIA™ AI Clinic Co-Pilot von BoomerangFX verzeichnet monatlich mehr als 1.000 autonome Konsultationen - vor dem Hintergrund einer rasanten Expansion in Nordamerika, Europa und im asiatisch-pazifischen Raum
des klinischen Kontexts in einer Vielzahl von Behandlungskategorien, darunter ästhetische Medizin, medizinische Gewichtsreduktion einschließlich GLP-1-Therapien, Hormonoptimierung, Dienstleistungen zur Förderung der Langlebigkeit, Haarwiederherstellung sowie sexuelle Gesundheit bei Männern und Frauen.Dr.
More news about: BoomerangFX
Apr 07, 2026, 08:14 ET Le copilote IA pour les cliniques, AUVIA™, de BoomerangFX dépasse les 1 000 consultations automatisées mensuelles avec une accélération rapide en Amérique du Nord, en Europe et en Asie-Pacifique.
éventail de domaines thérapeutiques, notamment la médecine esthétique, la perte de poids sous surveillance médicale (y compris les traitements à base de GLP-1), l'optimisation hormonale, les services liés à la longévité, la restauration capillaire et la santé sexuelle masculine et féminine.Le Dr Stephen
More news about: BoomerangFX
Apr 07, 2026, 08:14 ET El sistema AUVIA™ AI Clinic Co-Pilot de BoomerangFX supera las 1.000 consultas autónomas mensuales
contexto clínico en una amplia gama de categorías de tratamiento, que incluyen medicina estética, pérdida de peso médica (incluidas las terapias con GLP-1), optimización hormonal, servicios de longevidad, restauración capilar y salud sexual masculina y femenina.El Dr. Stephen Mulholland,
More news about: BoomerangFX
Apr 07, 2026, 08:00 ET GLP-1 Usage and Demand Surges, Reshaping Employer Benefits and Cost Strategies
New 9amHealth Report Finds GLP-1s Are Now a Top 3 Benefit—While Cost Remains the #1 BarrierSAN DIEGO, April 7, 2026 /PRNewswire/ -- GLP-1 medications have officially crossed from trending
More news about: 9amHealth
Apr 07, 2026, 08:00 ET Novo Nordisk's Wegovy® HD available now nationwide
Wegovy® label, inclusive of multiple formulations, including Wegovy® pill, and indications not available with other GLP-1 weight loss medicinesPLAINSBORO, N.J., April 7, 2026 /PRNewswire/
More news about: NOVO NORDISK INC.
Apr 07, 2026, 07:30 ET Bullish Invests in Singing Pastures, a Female-Founded Brand Reimagining Meat Sticks with Functional Protein
traditional crafting methods, like fermentation and slow-cooking, to create a more functional kind of protein."With the rise of GLP-1–influenced diets and a growing shift away from traditional protein bars, Singing Pastures is meeting evolving consumer needs with a more thoughtful approach
More news about: Bullish
Apr 07, 2026, 07:00 ET Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR
More news about: Ascletis Pharma Inc.
Apr 07, 2026, 07:00 ET 歌禮宣佈每日一次口服小分子GLP-1R激動劑ASC30與每日一次口服小分子胰澱素選擇性胰澱素受體激動劑ASC39的固定劑量復方制劑進行臨床開發
View original content to download multimedia:https://www.prnewswire.com/apac/zh/news-releases/glp-1rasc30asc39-302735627.htmlSOURCE 歌禮製藥有限公司
More news about: 歌禮製藥有限公司
Apr 03, 2026, 11:28 ET LEMME TACKLES THE HARDEST PART OF WEIGHT LOSS - KEEPING IT OFF - WITH NEW METABOLISM AKKERMANSIA CAPSULES
Lemme Metabolism arrives at a pivotal moment in the evolution of weight management. As GLP-1 medications reshape the conversation around metabolic health, maintaining results after weight loss has become an increasingly important focus for
More news about: Lemme
Apr 03, 2026, 06:02 ET 13 Press Releases You Need to See This Week
Including FDA approval of Lily's GLP-1 pill, March employment numbers, KitchenAid's new mixer and United's new TSA wait time tracker.Plus, a recap of timely Easter and New York International Auto Show news.NEW
More news about: PR Newswire
Apr 02, 2026, 13:02 ET RO LAUNCHES ELI LILLY'S KWIKPEN®, OFFERING PATIENTS A MORE CONVENIENT WAY TO TAKE ZEPBOUND®
The most effective GLP-1 medication is now available in a multi-dose penNEW YORK, April 2, 2026 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today announced
More news about: Ro
Apr 02, 2026, 12:03 ET La FDA aprueba Foundayo™ (orforglipron) de Lilly, la única pastilla GLP-1 para la pérdida de peso que puede tomarse a cualquier hora del día sin restricciones de comida o agua
los triglicéridos y la presión arterial sistólica. "En la actualidad, menos de 1 de cada 10 personas que podrían beneficiarse de una medicina GLP-1 están usándola, desalentadas por la falta de acceso, el estigma, la complejidad percibida o la creencia de que su condición no es lo suficientemente
More news about: Eli Lilly and Company
Apr 02, 2026, 09:00 ET Signant Health Appoints Specialist Physician and Clinical Research Expert Dr. Graham C. Ellis as Clinical Vice President to Strengthen Metabolic Disease and Diabetes Trial Capabilities
Scientific, where he oversaw the diabetes and metabolic disease portfolio. He has also served on a global expert panel for a recently completed GLP-1 cardiovascular outcomes trial in non-diabetic obese subjects, one of the most closely watched study designs in metabolic disease research today.In
More news about: Signant Health
Apr 02, 2026, 08:38 ET Clean Eatz Kitchen Publishes High-Fiber Meal Delivery Comparison as Colorectal Cancer Awareness Month Highlights Americans' Chronic Fiber Deficit
Kitchen offers chef-prepared, dietitian-designed frozen meals shipped nationwide. Meal plans include Weight Loss, High Protein, Gluten-Free, GLP-1, and Build Your Own, starting at $8.49 per meal. No subscriptions required. Always-free shipping on all meal plan orders. More at
More news about: CE Kitchen Inc
Apr 02, 2026, 00:04 ET Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at the American Diabetes Association's 2026 Scientific Sessions
Preclinical research on Caliway's fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies has been selected for presentation at the American Diabetes Association's 2026 Scientific Sessions.The presentation will be delivered by W. Timothy
More news about: Caliway Biopharmaceuticals
Apr 01, 2026, 11:30 ET FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
cholesterol, triglycerides and systolic blood pressure across all doses."Today, fewer than 1 in 10 people who could benefit from a GLP-1 are taking one, held back by access, stigma, perceived complexity or the belief that their condition isn't serious enough for treatment. We believe
More news about: Eli Lilly and Company
Apr 01, 2026, 09:00 ET From Commercialization to Global Leadership: Innogen (2591.HK) Unlocks the Strategic Value of Its Ultra-Long-Acting GLP-1 Receptor Agonist
inflection point and long-term valuation catalyst. Market analysis indicates that the global GLP-1 obesity market now accounts for over 80% of total GLP-1-related revenues, with obesity-to-diabetes revenue ratios approaching 9:1. In China, the obesity therapeutics market
More news about: Innogen
Apr 01, 2026, 09:00 ET Currax Expands Patient Access to FDA-Approved Obesity Treatment with PeekDirect™
Contrave, the #1 branded oral non-GLP-1 weight loss medication* is now available to self-funded employers through PeekBRENTWOOD, Tenn., April 1, 2026 /PRNewswire/ --
More news about: Currax Pharmaceuticals LLC
Apr 01, 2026, 08:30 ET Xtalks Announces its Life Science Webinar Calendar for April 2026
Cardiovascular Drug DevelopmentApr 14 - Fast-Tracking IVT mRNA Candidate Selection Through Smarter RNA DesignApr 15 - Accelerating GLP-1 Peptides to Market Through Integrated Formulation & Analytical DevelopmentApr 22 - Enhancing Accuracy in E&L with Machine LearningApr
More news about: Xtalks
Apr 01, 2026, 06:00 ET Hibiscus Health Achieves Contractual Integrity Validation from Validation Institute, Backed by $200,000 in Independent Guarantees
cardiometabolic screening without increased adverse health events; data shows 67% of screened employees had undetected risk and 90% lost weight without GLP-1 prescriptionsNEW YORK, April 1, 2026 /PRNewswire/ -- Hibiscus
More news about: Hibiscus Health
Mar 31, 2026, 20:49 ET 康霈獲選於美國糖尿病協會 ADA 2026 年會發表 CBL-514 與 GLP-1R 併用動物實驗數據
康霈減脂新藥 CBL-514 與 GLP-1R 類藥物併用之動物實驗研究，獲選於美國糖尿病協會 2026 年會（ADA 2026 Scientific Sessions）發表。本次將由國際知名肥胖與代謝醫學權威、康霈科學顧問W. Timothy Garvey, MD 擔任講者。美國糖尿病協會年會為全球規模最大、最具影響力的糖尿病與肥胖學術盛會之一，ADA每年發布的指引被視為全球臨床準則。獲選在全球糖尿病、肥胖與代謝領域最大的旗艦學術會議ADA的發表，顯示出CBL-514併用GLP-1R類減重藥物的研究方向與應用潛力，深獲國際代謝專家學者認同。康霈亦將於會議期間與國際業界專家、學者與國際大藥廠面對面交流，持續深化全球戰略布局。
More news about: 康霈生技